Product Description
Ataciguat is a novel anthranilic acid derivative that belongs to a new structural class of sGC activators which are capable of activating the oxidized form of sGC. Ataciguat, a nitric oxide-independent soluble guanylate cyclase activator, is being developed by Sanofi (previously sanofi-aventis), in collaboration with Mayo Clinic and National Center for Advancing Translational Sciences. Ataciguat is in phase II clinical trials for the treatment of aortic valve stenosis (Sourced from: https://drugs.ncats.io/drug/QP166M390Q)
Mechanisms of Action: sGC Activator
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Sanofi
Company Location: PARIS I0 75008
Company CEO: Paul Hudson
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 2: Neuralgia|Aortic Valve Stenosis|Calcinosis|Neuropathic Pain
Phase 1: Aortic Valve Stenosis
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| CAVS | P2 |
Completed |
Aortic Valve Stenosis|Calcinosis |
2018-07-01 |
|
| UL1RR024150 | P1 |
Completed |
Aortic Valve Stenosis |
2015-03-01 |
|
| SERENEATI | P2 |
Completed |
Neuropathic Pain |
2009-09-10 |
|
| SERENEATI | P2 |
Completed |
Neuralgia |
2009-06-01 |